Clinical Benefits of ABX464 for Ulcerative Colitis Revealed in Review Study

Clinical Benefits of ABX464 for Ulcerative Colitis Revealed in Review Study

282576

Clinical Benefits of ABX464 for Ulcerative Colitis Revealed in Review Study

Abivax has published a review study summarizing the mechanisms, as well as the previously undisclosed clinical benefits of ABX464, its treatment candidate for people with inflammatory diseases, including ulcerative colitis (UC). ABX464, undergoing clinical testing for several inflammatory diseases, will soon be evaluated in a Phase 2/3 trial for Crohn’s disease, the company announced. The review, “Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases,”…

You must be logged in to read/download the full post.